Holen Sie sich die Stockscreener-App
13.09
2.51%
0.32
Handel nachbörslich:
12.85
-0.24
-1.83%
Schlusskurs vom Vortag:
$12.77
Offen:
$12.84
24-Stunden-Volumen:
104.38K
Relative Volume:
0.77
Marktkapitalisierung:
$148.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-81.17M
KGV:
-1.2916
EPS:
-10.1344
Netto-Cashflow:
$-82.84M
1W Leistung:
+9.63%
1M Leistung:
+21.20%
6M Leistung:
-68.09%
1J Leistung:
-60.47%
1-Tages-Spanne:
$12.52
$13.88
1-Wochen-Bereich:
$11.80
$13.88
52-Wochen-Spanne:
$10.29
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Firmenname
Korro Bio Inc
Sektor
Branche
Telefon
617-468-1999
Adresse
60 FIRST STREET, CAMBRIDGE
Vergleichen Sie KRRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
13.09 | 148.84M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-16 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2024-08-14 | Eingeleitet | William Blair | Outperform |
| 2024-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2024-02-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-10 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-01-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-10-28 | Eingeleitet | Cowen | Outperform |
| 2019-10-28 | Eingeleitet | Goldman | Buy |
| 2019-10-28 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Korro Bio Inc Aktie (KRRO) Neueste Nachrichten
Korro Bio, Inc. (NASDAQ:KRRO) Shares Acquired by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Estimates Korro Bio FY2026 Earnings - Defense World
Wellington Management Group LLP Raises Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Nuveen Asset Management LLC Purchases 17,131 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Jane Street Group LLC Makes New Investment in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Deutsche Bank AG Buys 935 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Buy” from Analysts - Defense World
KRRO stock touches 52-week low at $11.06 amid sharp annual decline By Investing.com - Investing.com South Africa
KRRO stock touches 52-week low at $11.06 amid sharp annual decline - Investing.com Nigeria
Korro Bio, Inc. (NASDAQ:KRRO) Shares Purchased by BNP Paribas Financial Markets - Defense World
Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal year By Investing.com - Investing.com South Africa
Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com India
Korro Bio, Inc. (NASDAQ:KRRO) Stock Position Boosted by Northern Trust Corp - Defense World
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Brokers Offer Predictions for Korro Bio FY2025 Earnings - Defense World
Balyasny Asset Management L.P. Makes New Investment in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio Leadership Takes Stage at Three Major Healthcare Conferences: RBC, Jefferies, and Goldman Sachs - Stock Titan
Korro Bio (KRRO) Rating and Price Target Maintained by Chardan C - GuruFocus
Oppenheimer Adjusts Price Target for Korro Bio (KRRO) Amid Secto - GuruFocus
Oppenheimer Lowers Price Target for Korro Bio (KRRO) But Maintai - GuruFocus
Oppenheimer Lowers Price Target for Korro Bio (KRRO) But Maintains Rating | KRRO Stock News - GuruFocus
Oppenheimer Adjusts Korro Bio Price Target to $90 From $155, Maintains Outperform Rating - marketscreener.com
Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Korro Bio FY2025 EPS Estimate Raised by Cantor Fitzgerald - Defense World
Q2 Earnings Estimate for Korro Bio Issued By William Blair - Defense World
Q2 Earnings Forecast for Korro Bio Issued By HC Wainwright - Defense World
HC Wainwright Cuts Korro Bio (NASDAQ:KRRO) Price Target to $100.00 - Defense World
HC Wainwright Comments on Korro Bio FY2026 Earnings - Defense World
Wells Fargo & Company MN Raises Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
10,384 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Purchased by Barclays PLC - Defense World
10,347 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Raymond James Financial Inc. - Defense World
Korro Bio (KRRO) Price Target Cut Amid Strategic Adjustments | K - GuruFocus
Korro Bio price target lowered to $53 from $130 at H.C. Wainwright - Yahoo Finance
Korro Bio Reports Q1 2025 Financial Results - TipRanks
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Buy” by Analysts - Defense World
Korro Bio stock price target lowered to $100 at H.C. Wainwright By Investing.com - Investing.com South Africa
Korro Bio stock price target lowered to $100 at H.C. Wainwright - Investing.com Nigeria
4 more biotechs cut staff amid market tumult - BioPharma Dive
ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s layoffs - Endpoints News
Korro lays off 20% of staff to fund genetic med trials, Novo Nordisk partnership - Fierce Biotech
Korro Bio (KRRO) Analyst Rating Update: Price Target Lowered | K - GuruFocus
Korro Bio (KRRO) Price Target Reduced, Buy Rating Maintained | K - GuruFocus
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Korro (KRRO) Surpasses Q1 Revenue Expectations Amid Promising Cl - GuruFocus
Korro Bio Announces Strategic Workforce Reduction Plan - TipRanks
Korro Bio, Inc. SEC 10-Q Report - TradingView
Korro Bio, Inc. Reports Q1 2025 Financial Results and Updates on KRRO-110 Development for Alpha-1 Antitrypsin Deficiency - Nasdaq
JPMorgan Chase & Co. Sells 9,537 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Legal & General Group Plc Raises Stock Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Analysts Offer Predictions for Korro Bio FY2025 Earnings - Defense World
Finanzdaten der Korro Bio Inc-Aktie (KRRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Korro Bio Inc-Aktie (KRRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Agarwal Vineet | Chief Financial Officer |
Nov 11 '24 |
Sale |
70.00 |
800 |
56,000 |
0 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):